medigraphic.com
ISSN 1561-2996 (Electronic)
ISSN 0864-0289 (Print)

2012, Number 2

<< Back Next >>

Rev Cubana Hematol Inmunol Hemoter 2012; 28 (2)

Emergencies in Hematology II. Extravasation of cytostatics

Jaime-Fagundo JC, Arencibia-Núñez A, Romero-González A, Anoceto-Martínez A, Pavón-Morán V

Language: Spanish
References: 24
Page: 120-129
PDF size: 51.67 Kb.


ABSTRACT

Extravasation is one of the most serious complications during intravenous administration of cytostatics. In this paper we describe how an unintentional output of a cytostatic drug to the perivascular or subcutaneous space can occur during its administration, resulting from diverse factors. Its incidence is 0,1 to 6 %, according to different reports. There are dissimilar protocols for treatment and all agree that applying physical and pharmacological measures is the most important, as soon as each case require.


REFERENCES

  1. Larson DL. Treatment of tissue extravasation by antitumour agents. Cancer. 1982 May;49(9):1796-9.

  2. Schrijvers DL. Extravasation: a dreaded complication of chemotherapy. Ann Oncol. 2003;14(Suppl 3):iii26-30.

  3. Watanabe H, Ikesue H, Yoshida M, Yamamoto N, Sakamoto S, Koga T, et al. Protection against the extravasation of anticancer drugs by standardization of the management system. Hosp Pharm. 2008;43:571-6.

  4. Ener RA, Meglathery SB, Styler M. Extravasation of systemic hemato-oncological therapies. Ann Oncol. 2004 Jun;15(6):858-62.

  5. Johnston-Early A, Cohen MH. Mitomycin C-induced skin ulceration remote from infusion site. Cancer Treat Rep.1981;65:529.

  6. Conde-Estévez D, Mateu-de Antonio J. Actualización del manejo de extravasaciones de agentes citostáticos. Farm Hosp. 2011. doi:10.1016/j.farma.2011.01.002.

  7. Cox K, Stuart-Harris R, Abdini G. The management of cytotoxic-drug extravasation: guide-lines drawn up by a working party for the Clinical Oncological Society of Australia. Med J Aust. 1990 Feb 5;152(3):168.

  8. Jordan K, Behlendorf T, Surov A. Venous access ports: frequency and management of complications in oncology patients. Onkologie. 2008 Jul;31(7):404-10.

  9. Held-Warmkessel J. Accidental anthracycline extravasation. Nursing. 2007 Dec;37(12 Pt.1):72.

  10. Fenchel K, Karthaus M. Cytotoxic drug extravasation. Antibiot Chemother. 2000;50:144-8.

  11. Langstein HN, Duman H, Seelig D. Retrospective study of the management ofchemotherapeutic extravasation injury. Ann Plast Surg. 2002 Oct;49(4):369-74.

  12. Dorr RT. Antidotes to vesicant chemotherapy extravasations. Blood Rev. 1990 Mar;4(1):41-60.

  13. Bertelli G, Dini D, Forno G, Gozza A, Venturini M, Ballella G, et al. Dimethylsulphoxide and cooling after extravasation of antitumour agents. Lancet. 1993 Apr;341(8852):1098-9.

  14. Tyson AM, Gay WE. Successful experience utilizing dexrazoxane treatment for an anthracycline extravasation. Ann Pharmacother. 2010 May;44(5):922-5.

  15. Jordan K, Behlendorf T, Mueller F, Schmoll HJ. Anthracycline extravasation injuries: Management with dexrazoxane. Ther Clin Risk Manag 2009 Apr;5(2):361-6.

  16. Langer SW, Sehested M, Jensen PB. Anthracycline extravasation: a comprehensive review of experimental and clinical treatments. Tumori. 2009 May-Jun;95(3):273-82.

  17. Kane RC, McGuinn WD Jr, Dagher R. Dexrazoxane (Totect): FDA review and approval for the treatment of accidental extravasation following intravenous anthracycline chemotherapy. Oncologist. 2008 Apr;13(4):445-50.

  18. Reilly JJ, Neifeld JP, Rosenberg SA. Clinical course and management of accidental adriamycin extravasation. Cancer. 1977 Nov;40(5):2053-6.

  19. Upton J, Mulliken JB, Murray JE. Major intravenous extravasation injuries. Am J Surg.1979 Apr;137(4):497-506.

  20. El-Saghir N, Otrock Z, Mufarrij A, Abou-Mourad Y, Salem Z, Shamseddine A, et al. Dexrazoxane for anthracycline extravasation and GM-CSF for skin ulceration and wound healing. Lancet Oncol. 2004 May;5(5):320-1.

  21. Vano-Galvan S, Jaen P. Images in clinical medicine. Extravasation of epirubicin. N Engl J Med. 2009 May;360(20):2117.

  22. Madhavan S, Northfelt DW. Lack of vesicant injury following extravasation of liposomal Doxorubicin. J Natl Cancer Inst. 1995 Oct;87(20):1556-7.

  23. Saini A, Berruti A, Sperone P, Bitossi R, Tampellini M, Dogliotti L, et al. Recall inflammatory skin reaction after use of pegylated liposomal doxorubicin in site of previous drug extravasation. Lancet Oncol. 2006 Feb;7(2):186-7.

  24. Massó J, de la Vega A, Serrais JJ, Camacho C, Codina C, Pérez-Cardelús M, et al. Extravasación de citostáticos: la necesidad de disponer de un "kit" para una actuación inmediata. Farm Clin. 1993 Jun;10(5):416-21.




2020     |     www.medigraphic.com